Email updates

Keep up to date with the latest news and content from BMC Medical Research Methodology and BioMed Central.

Open Access Research article

Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening

Stuart G Baker1*, Diane Erwin2, Barnett S Kramer3 and Philip C Prorok1

Author Affiliations

1 Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, USA

2 Information Management Services, USA

3 Office of Disease Prevention, National Institutes of Health, USA

For all author emails, please log on.

BMC Medical Research Methodology 2003, 3:4  doi:10.1186/1471-2288-3-4

Published: 6 March 2003

Abstract

Background

Because randomized cancer screening trials are very expensive, observational cancer screening studies can play an important role in the early phases of screening evaluation. Periodic screening evaluation (PSE) is a methodology for estimating the reduction in population cancer mortality from data on subjects who receive regularly scheduled screens. Although PSE does not require assumptions about natural history of cancer it requires other assumptions, particularly progressive detection – the assumption that once a cancer is detected by a screening test, it will always be detected by the screening test.

Methods

We formulate a simple version of PSE and show that it leads to an upper bound on screening efficacy if the progressive detection assumption does not hold (and any effect of birth cohort is minimal) To determine if the upper bound is reasonable, for three randomized screening trials, we compared PSE estimates based only on screened subjects with PSE estimates based on all subjects.

Results

In the three randomized screening trials, PSE estimates based on screened subjects gave fairly close results to PSE estimates based on all subjects.

Conclusion

PSE has promise for obtaining an upper bound on the reduction in population cancer mortality rates based on observational screening data. If the upper bound estimate is found to be small and any birth cohort effects are likely minimal, then a definitive randomized trial would not be warranted.